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Transcriptional regulation of gene expression by hy-
poxia is an important, but yet only marginally charac-
terized mechanism by which organisms adapt to low
oxygen concentrations. The human hepatoma cell line
HepG2 is a widely used model for studying hypoxic in-
duction of the hematopoietic growth factor erythropoi-
etin. In an attempt to identify additional genes ex-
pressed in HepG2 cells during hypoxia, we differentially
screened a cDNA library derived from hypoxic (1% O2)
HepG2 cells using probes isolated from either normoxic
(21% O2) or hypoxic cells. Two genes were identified, one
encoding aldolase, a member of the glycolytic enzymes,
and the other encoding a1-antitrypsin which belongs to
the family of the acute phase (AP) responsive proteins.
Whereas hypoxic induction of glycolytic enzymes is well
established, oxygen-dependent regulation of AP genes
has not been reported so far. AP proteins are liver-de-
rived plasma proteins whose production during inflam-
mation is either up-regulated (positive AP reactants) or
down-regulated (negative AP reactants). In the present
study, we demonstrate that on the mRNA level hypoxic
stimulation of HepG2 cells led to (i) an induction of the
positive AP reactants a1-antitrypsin, a1-antichymotryp-
sin, complement C3, haptoglobin, and a1-acid glycopro-
tein; (ii) a down-regulation of the negative AP reactant
albumin; (iii) an up-regulation of the negative AP reac-
tant transferrin; and (iv) unchanged levels of the positive
AP reactants a- and b-fibrinogen as well as hemopexin.
Cycloheximide inhibited hypoxic up-regulation of AP
mRNAs demonstrating that de novo protein synthesis is
required for hypoxic induction. Nuclear run-on assays
indicate that the hypoxic increase in AP mRNAs is
mainly due to transcriptional regulation. The hypoxic
response was compared to AP stimulation by interleu-
kin 6. The results suggest that the adaptive response to
hypoxia overlaps with, but is not identical with, the AP
response mediated by interleukin 6.
Many insights into the mechanisms of oxygen-regulated
gene expression have been provided by the study of hypoxia-
induced erythropoietin (EPO)1 gene expression (1–3). The gly-
coprotein hormone EPO is the predominant stimulator of
erythropoiesis in bone marrow (4, 5). EPO is mainly produced
in fetal liver and adult kidney and, to some extent, also in adult
liver. Following exposure to hypoxia caused by high altitude or
anemia, for example, EPO levels in the blood increase 500- to
2000-fold (6). So far, the human hepatoma cell lines HepG2 and
Hep3B are the only permanent cell culture models available to
study oxygen-regulated EPO production (7). When cultured
under hypoxic conditions (1% versus 21% O2), both cell lines
show an increased EPO secretion which is mainly transcrip-
tionally regulated (8, 9).
Other genes have been found to be induced by hypoxia in
many different tissues as well (reviewed in Ref. 10). The wide
variety of these genes can be divided roughly into three classes.
The first class includes molecules that are favorable for the
adaption of the whole organism to general hypoxia, such as
EPO which elevates the oxygen transport capacity of the blood.
The second class comprises local acting factors that ensure the
survival of tissues exposed to local hypoxia due to high oxygen
consumption, reduced blood supply, or injury, for example. One
example is vascular endothelial growth factor (VEGF), a potent
angiogenic factor leading to increased vascularization of the
affected tissue. Hypoxic induction of VEGF has been found in
many different tissues and tumors (11), as well as in hepatoma
cells (12). The third class consists of intracellular factors in-
volved in the adaption of the cell to hypoxia, such as ubiqui-
tously expressed glycolytic enzymes which provide ATP
through anaerobic glycolysis (13) or transcription factors of the
Jun and Fos family which are induced by low oxygen in cardiac
myocytes and hepatoma cells (12, 14). Apart from the assump-
tion that the oxygen sensor might be a hemeprotein (15), nei-
ther the nature of this molecule nor the mechanisms leading to
enhanced gene expression have so far been characterized
clearly (16).
The HepG2 and Hep3B cell lines are not only used exten-
sively to study the regulation of EPO gene expression, but
represent also a common model system for investigating proin-
flammatory, cytokine-dependent expression of acute phase
(AP) proteins. The AP response is a protective physiological
reaction of the organism to disturbances of its homeostasis due
to inflammation caused by tissue injury, infection, or neoplastic
growth (reviewed in Refs. 17–19). Characteristics of an AP
response after local injury include the release of cytokines (e.g.
IL-1, IL-6, IL-11, tumor necrosis factor a, leukemia inhibitory
factor, and oncostatin M) which in turn induce a systemic
reaction manifested by, for example, fever, elevated secretion of
glucocorticoids, and changes in the concentration of a specific
set of plasma proteins, termed AP proteins, which are mainly
produced in the liver. These AP proteins are either up-regu-
lated (positive AP reactants) or down-regulated (negative AP
reactants) during the AP response. Protease inhibitors, blood
coagulation factors, transport proteins, and complement com-
ponents are examples of positive AP reactants which are com-
monly up-regulated 2- to 10-fold on both the mRNA and protein
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levels. Typical negative AP reactants include albumin and
transferrin. IL-6 has been shown to be the major mediator of
the AP response in both hepatoma cell lines in vitro and in rats
in vivo, but IL-1, tumor necrosis factor a, leukemia inhibitory
factor, and other cytokines are also capable of partially medi-
ating the AP response. The spectrum of AP proteins induced in
hepatoma cells, however, varies qualitatively and quantita-
tively between the different cytokines studied.
Unexpectedly, differential screening of a cDNA library de-
rived from hypoxic HepG2 cells identified hypoxic up-regula-
tion of an AP protein family member, encouraging us to analyze
the response of other AP proteins to hypoxia in HepG2 cells.
MATERIALS AND METHODS
Cell Culture—The human hepatoma cell line HepG2, obtained from
American Type Culture Collection (ATCC, HB-8065), was cultured in
Dulbecco’s modified Eagle’s medium (high glucose, Life Technologies,
Inc.) supplemented with 10% heat-inactivated (56 °C, 30 min) fetal calf
serum (Boehringer Mannheim), 100 units/ml penicillin, 100 mg/ml
streptomycin, non-essential amino acids, 2 mM L-glutamine, and 1 mM
sodium pyruvate (all Life Technologies, Inc.) in a humidified atmo-
sphere at 37 °C and 5% CO2. Oxygen tensions (pO2) in the incubator
(Forma Scientific) were either 140 mm Hg (21% v/v, normoxia) or 7 mm
Hg (1% v/v, hypoxia). For hypoxic induction, subconfluent HepG2 cells
were trypsinized, diluted in 100 ml/cm2 medium, and allowed to recover
for 24 h. The medium was replaced, and incubation at 1% O2 was
started. Cell density at this point was 1 3 104/cm2. For translation
inhibition, 20 mg/ml cycloheximide (Sigma) was added, and, for cytokine
induction, the media contained 20 ng/ml IL-6 (R & D Systems) and 1 mM
dexamethasone (Serva).
Library Construction and Differential Screening—HepG2 cells were
induced at 1% O2 for 16 h, and total RNA was isolated using the acid
guanidine thiocyanate-phenol-chloroform method (20). In order to min-
imize the effects of reoxygenation, care was taken to immediately lyse
the cells after removing them from the hypoxic incubator. Polyadeny-
lated mRNA was obtained by two rounds of oligo(dT)-cellulose spin
column chromatography (Pharmacia Biotech Inc.). A phage l-cDNA
library was constructed using the Uni-ZAP XR vector according to the
manufacturer’s instructions (Stratagene). Replica filters from this li-
brary were differentially screened with 32P-labeled total cDNA from
either hypoxic or normoxic HepG2 cells. cDNA synthesis was performed
for 1 h at 41.5 °C in 25 ml of 50 mM Tris/Cl (pH 8.3), 60 mM KCl, 3 mM
MgCl2, 10 mM dithiothreitol, 1 unit/ml RNasin (Promega), 1 mM each
dATP, dGTP, dTTP, 5 mM dCTP, using 2 mg of denatured (70 °C, 4 min)
poly(A)1 mRNA, 2 mg of oligo(dT)12–18 (Pharmacia), 50 mCi of
[a-32P]dCTP (Amersham), and 400 units of Moloney murine leukemia
virus reverse transcriptase (Life Technologies, Inc.). The RNA strand
was then removed by alkaline hydrolysis (0.5 M NaOH) for 15 min at
55 °C, and the cDNA was purified by Sephadex G-50 (Pharmacia)
chromatography as described (21). Hybridization to the filters was
performed using standard protocols (21). Clones which showed a
stronger signal with the hypoxic cDNA probe compared to the normoxic
probe were picked, plaque-purified, and in vivo-excised using the Ex-
Assist helper phage system (Stratagene). Single-stranded DNA was
prepared (21) to sequence the clones with the dideoxy chain termination
method (22). The clones were identified by comparing their sequence
to the GenBankTM/EMBL data library using the GCG program
package (23).
EPO Determination—EPO protein concentrations in the cell culture
supernatants were determined by a radioimmunoassay using 125I-EPO
(Amersham) and recombinant human EPO (Boehringer Mannheim) as
described previously (24).
Quantitative Northern Blot Analysis—Total RNA (10 mg) isolated
from HepG2 cells was denatured in formamide/formaldehyde and elec-
trophoresed through a 1% agarose gel containing 6% formaldehyde as
described (21). Following pressure blotting (Stratagene) to nylon mem-
branes (Biodyne A, Pall) and UV-cross-linking (Stratalinker, Strat-
agene), the filters were hybridized to labeled DNA probes in 50% form-
amide, 10% dextran sulfate, 5 3 Denhardt’s solution, 200 mg/ml
sonicated salmon sperm DNA, 1% SDS, 0.9 M NaCl, 60 mM NaH2PO4, 6
mM EDTA (pH 7.0) for 14 h at 42 °C. The filters were washed to a final
stringency of 55 °C in 0.1 3 SSC, 0.2% SDS and either exposed to x-ray
films using an intensifying screen (QUANTA III, DuPont NEN) or
quantified using a PhosphorImager (Molecular Dynamics). DNA probes
were obtained by restriction digestion of the plasmid followed by aga-
rose gel purification and labeled to a specific radioactivity of 1 3 109
dpm/mg (Prime-It II, Stratagene). The following plasmids were pur-
chased from the source noted: a1-antichymotrypsin, phACT235 (ATCC
61600); complement C3, pHLC3 (ATCC 59108); transferrin, pTf (ATCC
57228); albumin, pILMALB5 (ATCC 61356); a-fibrinogen, p304 (ATCC
59706); b-actin (Clontech). The following plasmids were kindly provided
by the individuals noted: haptoglobin, pHp/6, a1-acid glycoprotein,
p8AGP, and hemopexin, pHpxII (V. Poli); b-fibrinogen (P. C. Heinrich);
rat ribosomal RNA, p19 (I. Stancheva); and erythropoietin, pe49f (C.
Shoemaker, Genetics Institute). The VEGF plasmid pmVh was ob-
tained by subcloning a reverse transcription-polymerase chain reaction
amplification product of mouse brain RNA using the primers 59-cggaat-
tcGCGGGCTGCCTCGCAGTC-39 (sense) and 59-cgggatccTCACCGCCT-
TGGCTTGTCAC-39 (antisense) which span the entire coding region
(25). The ribosomal protein L28 cDNA was cloned from the HepG2 l
phage library.2 Unless otherwise stated, all cDNAs were of human
origin.
Determination of Transcription Rates—Nuclear run-on assays were
performed as described previously (26). Briefly, nuclei from 5 3 107
HepG2 cells cultured at normoxia or hypoxia for 48 h were isolated, and
transcriptional run-on reactions were performed in the presence of 250
mCi of [a-32P]UTP. The purified reaction products were hybridized to
dot-blot filters containing each 5 mg of a linearized plasmid DNA.
Following RNase A and proteinase K treatment, the signal intensities
were evaluated by PhosphorImager analysis. Northern blot analysis of
parallel cultures was performed to determine the steady-state mRNA
levels as described above.
RESULTS
Differential Screening of a HepG2 cDNA Library Reveals
Hypoxic Induction of Aldolase and a1-Antitrypsin mRNA—In
an attempt to clone new, hypoxia-regulated genes, we con-
structed and differentially screened a phage l-cDNA library
derived from HepG2 cells cultured at 1% O2 for 16 h. These
moderate hypoxic conditions did not significantly influence cell
growth and morphology compared to the normoxic control.
Following low density plating of 50,000 l clones, 8 clones were
selected that hybridized more strongly to total cDNA probes
derived from hypoxic HepG2 cells compared with total cDNA
derived from normoxic cells. Northern blot analysis revealed
that 2 out of these 8 clones corresponded to hypoxia-inducible
genes.
The first clone was identical with fructose-1,6-bisphosphate
aldolase A, starting 18 base pairs upstream of the AUG trans-
lation initiation codon (27). Northern blot hybridizations (Fig.
1) revealed a time-independent 2- to 3-fold accumulation of
aldolase mRNA during 24 to 72 h of hypoxia in HepG2 cells (see
below). This result was consistent with nuclear run-off exper-
iments in skeletal muscle cells, where aldolase transcription
2 C. Schuerer-Maly and R. H. Wenger, unpublished results.
FIG. 1.Northern blot analysis of hypoxia-induced HepG2 cells.
HepG2 cells were induced by exposure to 1% O2 for 24 h to 72 h at an
initial cell density of 1 3 104/cm2. Normoxic (21% O2) control experi-
ments were performed in parallel for each time point. Equal amounts
(10 mg) of total RNA were loaded. The signal obtained with a 28 S rRNA
probe was used to control for equal loading and blotting efficiency.
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rates have been reported to be induced 2- to 5-fold by low
oxygenation (13). During hypoxia, when anaerobic glycolysis is
the major source of ATP, the induction of glycolytic activity
ensures constant energy supply to the cell (28). The cloning of
a hypoxia-inducible glycolytic enzyme, however, confirmed the
accuracy of our differential screening approach.
The second clone was identified as a1-antitrypsin, beginning
11 bp upstream of the translational start site (29, 30). Its
mRNA was found to be induced in a time-dependent manner in
HepG2 cells (Fig. 1). Since a1-antitrypsin belongs to the group
of plasma proteins induced in hepatocytes during the AP re-
sponse (17), we tested if other members of this family are
induced by hypoxia as well.
Hypoxia Modulates Expression of mRNAs Encoding AP Pro-
teins in HepG2 Cells—A time course of hypoxic induction of
HepG2 cells was performed, including a normoxic control for
every time point. Because inducibility of EPO expression in
HepG2 cells has previously been shown to be reciprocally de-
pendent on cell confluency (7, 31), the cells were induced at a
low cell density for 24 to 72 h (see “Materials and Methods”).
After 72 h of hypoxic induction, experiments were terminated
since hypoxic passaging of cells was not practicable. Cell via-
bility after hypoxic incubation remained unchanged as judged
by trypan blue exclusion. In order to monitor the extent of
hypoxic induction of HepG2 cells, the EPO concentration in the
conditioned medium of every time point was determined by
radioimmunoassay. As shown in Fig. 2, EPO levels increased
under hypoxic conditions to 107 nanounits/cell after 24 h and
846 nanounits/cell after 72 h, corresponding to a maximum
accumulation of 25-fold after 72 h of hypoxia. This induction
was much higher than the 2- to 3-fold induction published
previously for this cell line (7), most probably due to optimized
cell culture conditions.3 When cells were plated at 8-fold higher
density, the inducibility decreased even though confluency was
still not reached (data not shown).
Northern blot analysis was then performed using hybridiza-
tion probes for EPO and VEGF, as well as positive AP reactants
(a1-antitrypsin, a1-antichymotrypsin, complement C3, hapto-
globin, a1-acid glycoprotein, hemopexin, and a- and b-fibrino-
gen) and negative AP reactants (albumin and transferrin). The
signals were quantitated by PhosphorImager analysis and cor-
rected for differences in loading and blotting by hybridization
to a 28 S ribosomal probe as exemplified in Fig. 1. b-Actin,
another commonly used normalization probe, was found to be
reproducibly induced by a factor of approximately 1.5 (Figs. 1
and 3A). A weak transcriptional activation of b-actin by hy-
poxia has already been reported in rat skeletal muscle cells
(13). Hence, b-actin is inappropriate for normalization of these
experiments. Hypoxic response of HepG2 cells was verified by
analyzing the induction rates for EPO and VEGF. Under the
stated experimental conditions, EPO and VEGF mRNAs were
induced 3.5- to 7-fold and 4.5- to 11-fold, respectively, after 24
h to 72 h of hypoxia (Fig. 3A). Fig. 3B revealed a similar 3- to
7-fold time-dependent induction of AP protein-encoding
mRNAs (a1-antichymotrypsin, complement C3, a1-antitrypsin,
and haptoglobin) after 48 h to 72 h of hypoxic incubation. The
negative AP reactant albumin was down-regulated by hypoxia,
as it is during the in vivo AP response. Surprisingly, although
fibrinogens are among the most prominent positive AP reac-
tants induced by IL-6 in HepG2 cells (17), mRNA levels of the
coordinately expressed a- and b-fibrinogen genes (32, 33) were
not significantly affected by hypoxia. The positive AP reactants
a1-acid glycoprotein and hemopexin were also only marginally
regulated by oxygen. Moreover, transferrin, which is down-
regulated by IL-6 and tumor necrosis factor a in HepG2 cells in
vitro and also during the AP response in vivo (17), was induced
by hypoxia up to 4.5-fold. Hypoxic exposure for up to 24 h at an
8-fold higher initial cell density did not significantly induce
mRNA levels of AP proteins or of EPO or VEGF (not shown), in
accordance with the previously reported cell density depend-
ence of EPO expression in HepG2 cells (7). Time course and
extent of hypoxic induction of AP mRNAs was similar to the
mRNAs encoding EPO and VEGF. A maximum was reached at3 R. H. Wenger, unpublished observations.
FIG. 2. EPO protein levels in the supernatant of HepG2 cul-
tures.HepG2 cells were induced by hypoxia as described in Fig. 1. EPO
concentrations were determined by a radioimmunoassay using recom-
binant human EPO. Results are expressed as nanounits of EPO per cell.
FIG. 3. Time-dependent induction of steady-state mRNA levels
following hypoxic treatment of HepG2 cells. Northern blots were
quantified by PhosphorImager analysis and normalized by hybridiza-
tion to a 28 S rRNA probe. Results are shown as percentage of the
corresponding normoxic control. A, hypoxic induction of non-AP genes.
B, hypoxic induction of AP genes.
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72 h of incubation, whereas hypoxic induction of aldolase
mRNA remained relatively constant over the time points ex-
amined (Fig. 3A). In summary, these results suggest a common
mechanism for hypoxic induction of EPO, VEGF, and AP
mRNAs and possibly a distinct mechanism for induction of the
glycolytic enzyme aldolase.
Hypoxia Regulates a Specific Set of AP Genes in HepG2
Cells—Among the proinflammatory cytokines, IL-6 has been
reported to be the major activator of AP gene expression in
hepatoma cells (17). To compare the hypoxic AP induction with
cytokine stimulation, HepG2 cells were cultured up to 3 days in
the presence of 20 ng/ml IL-6 and 1 mM dexamethasone, which
is known to be required for full IL-6 activation (17). The results
of the combined IL-6/dexamethasone treatment of HepG2 cells,
performed under the same experimental conditions as for hy-
poxic stimulation, are shown in Fig. 4. A strong induction (7- to
35-fold) was observed for haptoglobin, a1-antichymotrypsin,
and the fibrinogen genes. a1-Acid glycoprotein, hemopexin,
complement C3, and a1-antitrypsin were only moderately in-
duced (1.5- to 4-fold). Albumin and transferrin were down-
regulated by IL-6/dexamethasone after 1 to 2 days. However,
this effect could be reversed after long-term (3 days) treatment.
Dexamethasone alone did not influence AP gene expression
either under normoxic or hypoxic conditions, and the combina-
tion of IL-6/dexamethasone with hypoxia did not result in any
additive effects (not shown).
A comparison of hypoxic and IL-6/dexamethasone treatment
of HepG2 cells in vitro opposed to the AP response in vivo is
shown in Table I. The results suggest that most of the liver AP
genes can also be induced by IL-6/dexamethasone in HepG2
cells. However, Table I revealed a hypoxia-specific AP mRNA
pattern in HepG2 cells which was overlapping but not identical
with the cytokine-induced pattern observed in vitro and in vivo.
This pattern also did not correspond to the two classes of AP
proteins, proposed by Baumann and Gauldie (34) based on
their hormone requirement.
Transcriptional Regulation of Hypoxic AP Gene Expres-
sion—To determine to what extent transcriptional and post-
transcriptional mechanisms contribute to the hypoxic increase
of AP steady-state mRNA levels, Northern blot and nuclear
run-on assays were performed using HepG2 cells which were
induced for 48 h. Following background subtraction of the
signal obtained with the vector alone, the induction rates were
normalized to the signal derived from the ribosomal protein
L28 cDNA probe. Normalization to L28 was chosen because, in
contrast to the glycolytic enzymes and b-actin (see above), L28
was not regulated by oxygen concentrations.2 The induction
rate in this particular set of experiments was rather low. How-
ever, the rates were comparable with those obtained with
VEGF and aldolase probes, suggesting that the overall stimu-
lation of the cells was somewhat reduced. The comparison of
the induction rates in Northern blots and run-on assays shown
in Fig. 5 indicates that hypoxic induction of the AP mRNAs
encoding a1-antichymotrypsin, transferrin, and a1-antitrypsin
is due mainly to the change in transcription rates.
Hypoxic Induction of AP mRNA Levels Is Translation-de-
pendent—Cycloheximide, a potent inhibitor of translation, has
been reported to block the hypoxic induction of mRNAs encod-
ing EPO (15) and glycolytic enzymes (35, 36), most probably by
inhibiting the synthesis of a transcription factor required for
oxygen-regulated EPO gene expression (37). To test whether
AP genes are induced by hypoxia through a similar mechanism,
we exposed HepG2 cells to 1% O2 for 48 h with or without 20
mg/ml cycloheximide. As shown in Fig. 6, this treatment abro-
gated hypoxic induction of a1-antichymotrypsin, transferrin,
and a1-antitrypsin mRNAs, indicating that a de novo trans-
lated protein is required for hypoxic stimulation, as it is known
for the induction of EPO and glycolytic enzymes.
DISCUSSION
Putative Physiological Functions of Hypoxic AP Protein In-
duction—The results presented in this study are the first dem-
onstration of hypoxic induction of AP genes in HepG2 cells, a
hepatoma cell line known to express EPO (7) and VEGF (this
study) in an oxygen-dependent manner. Assuming that hypoxic
modulation of AP genes in cell culture reflects the in vivo
situation, this finding might have important implications for
the mechanisms through which an organism responds to low
oxygen supply. The widespread oxygen-sensing and signaling
mechanisms leading to increased expression of specific genes
such as EPO might affect other genes also, including AP re-
sponsive genes, whose products could play a role for the adap-
tion of the organism to hypoxic conditions. It is attractive to
postulate that the AP proteins are involved in maintaining
efficient oxygen uptake and enhancing oxygen transport
capacity.
Both, a1-antitrypsin and a1-antichymotrypsin inhibit pro-
teases (neutrophil-derived elastase and cathepsin G, respec-
tively) that otherwise could lead to proteolytic degradation of
lung tissue and emphysema, thereby affecting general oxygen
supply to the organism (38, 39). It is tempting to speculate that
induction of these protease inhibitors might contribute to pro-
tecting the lung from tissue damage caused by neutrophils
which are known to invade the lung of hypoxic mice (40).
Since iron is an essential component for hemoglobin synthe-
FIG. 4. IL-6 induction of AP genes in HepG2 cells. The cells were
induced with 20 ng/ml IL-6 in the presence of 1 mM dexamethasone
(DXM). Steady-state mRNA levels were determined as described in
Fig. 3.
TABLE I
Regulation of AP mRNAs by hypoxia and IL-6/dexamethasone in
HepG2 cells in vitro and AP response in human serum in vivo
AP protein
HepG2 cellsa Human seruma
1% O2 IL-6/dexamethasone AP response
b
a1-Antichymotrypsin 1 1 1
Complement C3 1 (1) 1
Transferrin 1 2c 2
a1-Antitrypsin 1 (1) 1
Haptoglobin 1 1 1
a1-Acid glycoprotein (1) 1 1
a-Fibrinogen 0 1 1
b-Fibrinogen 0 1 1
Hemopexin 0 1 0
Albumin 2 2c 2
a 0, no effect; 2, inhibition; (1), #2-fold induction; 1, induction.
b Ref. 17.
c Weak IL-6 induction after prolonged incubation.
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sis during red cell formation in bone marrow, hypoxic up-
regulation of the iron transport protein transferrin might sup-
port EPO-induced erythropoiesis by enhanced iron supply.
Indeed, increased transferrin serum levels in mice (41) and rats
(42) that were exposed to 50% atmospheric pressure for 1 to 3
days have been reported. Likewise, hypoxic induction of the
hemoglobin-binding transport protein haptoglobin might sus-
tain enhanced erythropoiesis by preventing the loss of heme
iron from the kidney. Besides many other functions, comple-
ment C3 is involved in erythrocyte degradation, thereby main-
taining constant erythrocyte lifespan (reviewed in Refs. 43 and
44). Complement C3 induction might be required to keep the
balance between plasma complement C3 concentrations and
decay accelerating factor under conditions of enhanced eryth-
ropoiesis. Decay accelerating factor is present on the surface of
erythrocytes and protects them from complement-mediated cell
lysis.
Putative Pathological Functions of Hypoxic AP Protein In-
duction—Hypoxia-induced AP gene expression might also con-
fer pathological processes. In Alzheimer’s disease, for example,
increased expression of a1-antichymotrypsin and complement
components such as C3 have been reported (45, 46). A tight
association between a1-antichymotrypsin and bA4-protein in
senile b-amyloid plaques suggests that a1-antichymotrypsin
might be involved in the pathophysiology of this disease. In-
deed, a1-antichymotrypsin has been demonstrated to promote
assembly of Alzheimer b-protein into filaments in vitro (47). A
brain-specific AP response has been proposed because astro-
cytes, which synthesize a1-antichymotrypsin and complement
C3, respond to brain-derived cytokines (48–50). However, a
cause for increased cytokine expression in the brain has not
clearly been established (51). Based on the results presented in
this study, we postulate that hypoxia could stimulate a1-anti-
chymotrypsin and complement C3 production. In support of the
postulate that the brain can produce AP proteins in an oxygen-
dependent manner, we recently found hypoxia-inducible EPO
expression in brain (52). Further experiments suggest that
astrocytes are the site of brain EPO expression (53).4 Hypoxic
stimulation of primary astrocytes will be performed to investi-
gate if a1-antichymotrypsin is also inducible by low oxygen
concentrations in this cell type. Hypoxic induction of a1-anti-
chymotrypsin and other AP proteins in astrocytes might pro-
vide new insights into the molecular pathogenesis of plaque
formation in the brain.
Is There a Common Mediator of Oxygen- and Cytokine-de-
pendent AP Gene Induction?—Our finding that most AP re-
sponsive genes are inducible in an oxygen-dependent manner
raises the question as to whether every AP gene is individually
regulated by either hypoxia or proinflammatory cytokines or
whether a common oxygen- and cytokine-dependent factor is
able to regulate AP gene expression. Possible common mecha-
nisms might include HepG2-derived hypoxia-inducible cyto-
kines, protein kinases, and/or transcription factors. Interest-
ingly, IL-6 has recently been shown to be hypoxia-inducible in
astrocytes (54) and endothelial cells (55). The IL-6 activating
transcription factor C/EBPb seems to be critically involved in
hypoxic IL-6 induction (55). Thus, hypoxia-inducible IL-6
might be a candidate mediator of AP gene induction in HepG2
cells. However, the question of whether parenchymal hepato-
cytes are able to produce IL-6, which in turn could activate
hepatic gene expression in an autocrine fashion, is a matter of
debate (56, 57). In addition, the pattern of genes induced by
either IL-6 or hypoxia (see Table I) is clearly different, provid-
ing evidence that hypoxic AP gene expression cannot simply be
attributed to an autocrine IL-6 activation. Since the transcrip-
tion factor C/EBPb is not only involved in IL-6 induction ob-
served in nonhepatic cells, but also mediates IL-6-induced AP
gene expression in hepatocytes (58), we are currently examin-
ing the effect of hypoxia on the C/EBP family of transcription
factors.
Cellular stress could be another common inducer of AP pro-
teins and EPO under hypoxic conditions. Heat shock is a well-
established activator of stress-responsive genes and the ques-
tion arose whether heat shock and hypoxia are two different
stimuli resulting in the expression of the same genes. Several
lines of evidence indicate that this is not the case. Despite
reports that anoxia (59) and anoxia followed by reoxygenation
(60) induce heat-shock proteins in mammalian cell lines, oxy-
gen tensions similar to those used in our experiments failed to
induce the major heat-shock proteins (3). On the other hand,
IL-6 does not induce the heat-shock protein Hsp70 in Hep3B
cells (61). Furthermore, neither EPO (3, 15) nor AP proteins
(60) are induced by heat shock in hepatoma cells. In this con-
text, it is noteworthy that although the oxygen tension in our
experiments (7 mmHg) is 21-fold reduced compared to ambient
air (140 mm Hg), it represents only about a 3.5-fold reduction
compared to the average oxygen tension measured in vivo at
the liver surface (approximately 25 mm Hg, Ref. 62). This
4 H. H. Marti, R. H. Wenger, L. A. Rivas, U. Stranmann, M. Digicay-
lioglu, V. Henn, Y. Yonekawa, C. Bauer, and M. Gassman, submitted
for publication.
FIG. 5. Transcriptional regulation of hypoxia-inducible AP
gene expression. Northern blot analysis and nuclear run-on assays
were performed using parallel HepG2 cultures induced at 1% O2 for 48
h. Signal intensities were corrected for vector background, normalized
to the signal obtained with a ribosomal protein L28 cDNA probe, and
expressed as percentage of the normoxic control. The mean values of
two independent experiments are shown. Run-on signals for VEGF
were less than 2-fold above background level and hence not included in
this figure. n.d., not detectable.
FIG. 6. Effect of cycloheximide on hypoxic AP gene induction.
HepG2 cells were induced for 48 h at 1% O2 with or without 20 mg/ml
cycloheximide, and total RNA was analyzed by Northern blotting as
described in Fig. 3.
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suggests that the hypoxic conditions used in our experiments
represent a rather mild physiological stimulant compared to
the pathological conditions of anoxia or heat shock, both of
which result in heat-shock protein expression.
In summary, inflammation-independent hypoxic induction of
AP protein gene expression in hepatic and probably also extra-
hepatic tissues could shed new light on the mechanisms by
which organisms adapt to hypoxia.
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